about
Personalized medicine in Europe: not yet personal enough?Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.Pharmacogenetic determinants of anti-cancer drug activity and toxicity.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerPharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsClinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersDihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteersLack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia.Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin.Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis.A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.Different recommendations for daptomycin dosing over time in patients with severe infections.Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily.Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report.
P50
Q33577079-B7403106-E79F-4129-A185-497E59A13CCBQ33622988-1294FFB8-8BA3-4405-AF33-803CF17BFF7FQ34322733-FC14E7F3-9DC5-46E2-958B-008431DD9CEEQ34806780-A10AD69F-B730-459F-9C01-CB124577D153Q35803848-65608DAE-4A75-48E8-9BDF-40AFE8B05165Q35918752-388D1D9F-D5BB-464E-BC17-49B2C82B5531Q36117656-2285EF47-79A3-40B0-8F46-1D10C89FECE7Q36615612-99D3C18D-D7ED-4B7F-868C-75DCAB6716B5Q36622317-4CB12699-53EB-42A0-A0A4-034A35D0B740Q37053912-6EADB0F9-1F87-4468-9C41-B33D343F7E8EQ37321407-6C2C0F6F-4347-459A-9AB8-CF11F3AD5049Q37905064-57146B1D-CEBB-451F-AC99-BD81151F8EBEQ38052835-2C32421B-993C-4297-9DA6-E0637BCE734CQ38100704-583D4279-151C-4EE2-BC01-D2A40760CBB0Q38513661-C981CEDA-DDC7-4057-8664-0A52A55319EAQ38910072-B74F2E48-29A5-406A-96DA-130FF320B808Q40231420-FDF723C9-7C84-491F-AD3C-854A2A3E3D1AQ40332713-07C07F23-0A7E-4B92-AA84-9B54A43ABD54Q40564796-D38D670B-2D57-4099-B037-06625B3124E3Q41298572-BA6EA9E6-B9EF-421F-AD12-E29112780D65Q41872813-18E54A3F-9855-49BD-BB04-1A8DDF568F94Q41960102-FCA3B96E-9BCE-4D03-9B4C-4DE905143749Q42520236-10236988-4E7D-41C9-8D9B-1EE88960B352Q42529523-1B87FB25-182E-4808-92F3-20F89A543AB0Q43136493-68BAD857-8017-4CD6-8B35-E5AAD168B82FQ43146760-B4D2E68B-B7A6-4008-8C41-60BA8EFFE111Q43296441-B4112235-3829-434B-A523-D63CC61A4EF2Q43791713-44E8B7E6-5A62-4ABB-B01F-16E5FF745DE0Q43820801-74C53D79-2C42-4DCB-A981-6A2E570899C4Q43835722-91E87CCB-D53B-4AD6-8E72-123A3628C570Q44155889-0833A38D-5693-4482-960F-254050705D31Q44157276-AB571252-FB9A-4D97-B750-667600F872BCQ44233281-83445ECF-C83E-45F4-9347-32D493FE0E0DQ44259174-79389648-2207-4D7A-9BA9-F84CFAF58E6FQ44785015-6BF08605-B231-4F59-BC1B-55BC301B5688Q44795394-BE0F9447-3083-41D3-A574-EDDD949F5BB6Q45203387-D762FEA9-7BEA-4080-8434-EF6D49688DC3Q45873401-53889F27-5DE3-413B-9339-D3552F21FA85Q46328545-2E385A7B-68F4-47C6-AABA-E3DD6BAEFF08Q46461094-DCDF477F-AE34-4B04-95CA-361412BBB8E3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonello Di Paolo
@ast
Antonello Di Paolo
@en
Antonello Di Paolo
@es
Antonello Di Paolo
@nl
type
label
Antonello Di Paolo
@ast
Antonello Di Paolo
@en
Antonello Di Paolo
@es
Antonello Di Paolo
@nl
prefLabel
Antonello Di Paolo
@ast
Antonello Di Paolo
@en
Antonello Di Paolo
@es
Antonello Di Paolo
@nl
P106
P1153
7004206615
P21
P31
P496
0000-0002-2661-6183